Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report) was down 5% during trading on Thursday . The company traded as low as $14.33 and last traded at $14.53. Approximately 696,839 shares changed hands during trading, a decline of 95% from the average daily volume of 13,242,744 shares. The stock had previously closed at $15.29.
Regencell Bioscience Stock Down 2.8%
Hedge Funds Weigh In On Regencell Bioscience
A hedge fund recently bought a new stake in Regencell Bioscience stock. Greenfield Savings Bank acquired a new position in shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,000 shares of the company's stock, valued at approximately $187,000. 0.13% of the stock is currently owned by institutional investors.
About Regencell Bioscience
(
Get Free Report)
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regencell Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regencell Bioscience wasn't on the list.
While Regencell Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
